[A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):]

Eiji Oki, Yoshihiro Kakeji, Rintaro Yoshida, Keisuke Ikeda, Kojiro Nishida, Tadashi Koga, Akinori Egashira, Eriko Tokunaga, Masaru Morita, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We are conducting a prospective randomized trial to evaluate the survival benefit of adjuvant chemotherapy with S-1 (tegafur, gimeracil, oteracil potassium) and UFT (uracil-tegafur) after curative surgery for patients with Stage II and III rectal cancer. Patients are randomized to either administration of UFT (control) or S-1. UFT was orally administered for 5 days (400 mg/m2/day) followed by two days rest for a year. S-1 was orally administered for 4 weeks (80 mg/m2/day) followed by two weeks rest for a year. The primary endpoint is relapse-free survival (RFS) rate, and the secondary endpoints are overall survival time (OS) and frequency or level of adverse events. We aim to include 400 patients in each of the treatment groups and assume that the registration period will last until 2009.

Original languageEnglish
Pages (from-to)138-143
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Publication statusPublished - Jun 1 2006

Fingerprint

Adjuvant Chemotherapy
Rectal Neoplasms
Randomized Controlled Trials
Tegafur
Survival
Uracil
Potassium
Therapeutics
Survival Rate
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

[A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):]. / Oki, Eiji; Kakeji, Yoshihiro; Yoshida, Rintaro; Ikeda, Keisuke; Nishida, Kojiro; Koga, Tadashi; Egashira, Akinori; Tokunaga, Eriko; Morita, Masaru; Baba, Hideo; Maehara, Yoshihiko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 33, 01.06.2006, p. 138-143.

Research output: Contribution to journalArticle

Oki, Eiji ; Kakeji, Yoshihiro ; Yoshida, Rintaro ; Ikeda, Keisuke ; Nishida, Kojiro ; Koga, Tadashi ; Egashira, Akinori ; Tokunaga, Eriko ; Morita, Masaru ; Baba, Hideo ; Maehara, Yoshihiko. / [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):]. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2006 ; Vol. 33. pp. 138-143.
@article{379b90275cb04483a4a1414a0cc7d07a,
title = "[A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):]",
abstract = "We are conducting a prospective randomized trial to evaluate the survival benefit of adjuvant chemotherapy with S-1 (tegafur, gimeracil, oteracil potassium) and UFT (uracil-tegafur) after curative surgery for patients with Stage II and III rectal cancer. Patients are randomized to either administration of UFT (control) or S-1. UFT was orally administered for 5 days (400 mg/m2/day) followed by two days rest for a year. S-1 was orally administered for 4 weeks (80 mg/m2/day) followed by two weeks rest for a year. The primary endpoint is relapse-free survival (RFS) rate, and the secondary endpoints are overall survival time (OS) and frequency or level of adverse events. We aim to include 400 patients in each of the treatment groups and assume that the registration period will last until 2009.",
author = "Eiji Oki and Yoshihiro Kakeji and Rintaro Yoshida and Keisuke Ikeda and Kojiro Nishida and Tadashi Koga and Akinori Egashira and Eriko Tokunaga and Masaru Morita and Hideo Baba and Yoshihiko Maehara",
year = "2006",
month = "6",
day = "1",
language = "English",
volume = "33",
pages = "138--143",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

}

TY - JOUR

T1 - [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):]

AU - Oki, Eiji

AU - Kakeji, Yoshihiro

AU - Yoshida, Rintaro

AU - Ikeda, Keisuke

AU - Nishida, Kojiro

AU - Koga, Tadashi

AU - Egashira, Akinori

AU - Tokunaga, Eriko

AU - Morita, Masaru

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2006/6/1

Y1 - 2006/6/1

N2 - We are conducting a prospective randomized trial to evaluate the survival benefit of adjuvant chemotherapy with S-1 (tegafur, gimeracil, oteracil potassium) and UFT (uracil-tegafur) after curative surgery for patients with Stage II and III rectal cancer. Patients are randomized to either administration of UFT (control) or S-1. UFT was orally administered for 5 days (400 mg/m2/day) followed by two days rest for a year. S-1 was orally administered for 4 weeks (80 mg/m2/day) followed by two weeks rest for a year. The primary endpoint is relapse-free survival (RFS) rate, and the secondary endpoints are overall survival time (OS) and frequency or level of adverse events. We aim to include 400 patients in each of the treatment groups and assume that the registration period will last until 2009.

AB - We are conducting a prospective randomized trial to evaluate the survival benefit of adjuvant chemotherapy with S-1 (tegafur, gimeracil, oteracil potassium) and UFT (uracil-tegafur) after curative surgery for patients with Stage II and III rectal cancer. Patients are randomized to either administration of UFT (control) or S-1. UFT was orally administered for 5 days (400 mg/m2/day) followed by two days rest for a year. S-1 was orally administered for 4 weeks (80 mg/m2/day) followed by two weeks rest for a year. The primary endpoint is relapse-free survival (RFS) rate, and the secondary endpoints are overall survival time (OS) and frequency or level of adverse events. We aim to include 400 patients in each of the treatment groups and assume that the registration period will last until 2009.

UR - http://www.scopus.com/inward/record.url?scp=84925554298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925554298&partnerID=8YFLogxK

M3 - Article

C2 - 16897990

AN - SCOPUS:84925554298

VL - 33

SP - 138

EP - 143

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

ER -